See more : Otis Worldwide Corp (4PG.DE) Income Statement Analysis – Financial Results
Complete financial analysis of TELA Bio, Inc. (TELA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TELA Bio, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Oji Holdings Corporation (3861.T) Income Statement Analysis – Financial Results
- Ophir Gold Corp. (KPZIF) Income Statement Analysis – Financial Results
- O2Micro International Limited (OIIM) Income Statement Analysis – Financial Results
- BioArctic AB (publ) (BRCTF) Income Statement Analysis – Financial Results
- Acrel Co.,Ltd. (300286.SZ) Income Statement Analysis – Financial Results
TELA Bio, Inc. (TELA)
About TELA Bio, Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 58.45M | 41.42M | 29.46M | 18.21M | 15.45M | 8.27M | 4.25M |
| Cost of Revenue | 18.34M | 14.37M | 10.65M | 6.98M | 6.17M | 5.33M | 1.71M |
| Gross Profit | 40.11M | 27.04M | 18.81M | 11.23M | 9.27M | 2.94M | 2.53M |
| Gross Profit Ratio | 68.62% | 65.30% | 63.85% | 61.68% | 60.03% | 35.56% | 59.65% |
| Research & Development | 9.62M | 8.94M | 6.74M | 4.26M | 4.15M | 4.34M | 5.79M |
| General & Administrative | 14.89M | 13.86M | 12.46M | 10.14M | 6.22M | 4.90M | 4.96M |
| Selling & Marketing | 59.68M | 43.25M | 29.06M | 22.11M | 18.06M | 13.65M | 8.71M |
| SG&A | 74.57M | 57.11M | 41.52M | 32.25M | 24.28M | 18.55M | 13.67M |
| Other Expenses | 0.00 | -10.00K | -228.00K | 45.00K | 351.00K | 70.00K | 94.00K |
| Operating Expenses | 84.19M | 66.05M | 48.26M | 36.51M | 28.43M | 22.88M | 19.46M |
| Cost & Expenses | 102.53M | 80.43M | 58.91M | 43.49M | 34.61M | 28.22M | 21.17M |
| Interest Income | 0.00 | 4.05M | 3.60M | 3.56M | 3.61M | 0.00 | 0.00 |
| Interest Expense | 5.22M | 4.05M | 3.60M | 3.56M | 3.61M | 1.80M | 4.56M |
| Depreciation & Amortization | 808.00K | 1.19M | 535.00K | 525.00K | 582.00K | 1.25M | 761.00K |
| EBITDA | -40.63M | -39.06M | -29.14M | -24.71M | -18.23M | -18.04M | -16.02M |
| EBITDA Ratio | -69.51% | -94.20% | -100.73% | -138.53% | -121.79% | -225.09% | -378.54% |
| Operating Income | -44.08M | -39.01M | -29.45M | -25.28M | -19.16M | -17.78M | -16.92M |
| Operating Income Ratio | -75.40% | -94.18% | -99.96% | -138.77% | -124.06% | -214.91% | -398.68% |
| Total Other Income/Expenses | -2.59M | -5.29M | -3.83M | -3.52M | -3.26M | -3.31M | -4.41M |
| Income Before Tax | -46.66M | -44.30M | -33.28M | -28.79M | -22.43M | -21.09M | -21.33M |
| Income Before Tax Ratio | -79.83% | -106.95% | -112.94% | -158.10% | -145.18% | -254.92% | -502.57% |
| Income Tax Expense | 0.00 | 41.00K | 2.83M | 3.08M | 3.38M | -1.51M | 4.65M |
| Net Income | -46.66M | -44.34M | -36.11M | -31.88M | -25.80M | -21.09M | -21.33M |
| Net Income Ratio | -79.83% | -107.05% | -122.56% | -175.03% | -167.05% | -254.92% | -502.57% |
| EPS | -2.04 | -2.73 | -2.49 | -2.46 | -2.26 | -3.25 | -3.29 |
| EPS Diluted | -2.04 | -2.73 | -2.49 | -2.46 | -2.26 | -3.25 | -3.29 |
| Weighted Avg Shares Out | 22.87M | 16.27M | 14.47M | 12.93M | 11.41M | 6.49M | 6.49M |
| Weighted Avg Shares Out (Dil) | 22.87M | 16.27M | 14.47M | 12.93M | 11.41M | 6.49M | 6.49M |
TELA Bio to Participate in Piper Sandler's 36th Annual Healthcare Conference
MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler's 36th Annual Healthcare Conference.
TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript
TELA Bio, Inc. (NASDAQ:TELA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President, Gilmartin Group Tony Koblish - President & Chief Executive Officer Roberto Cuca - Chief Operating Officer &...
TELA Bio, Inc. (TELA) Reports Q3 Loss, Lags Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA...
TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
MALVERN, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced the closing of its previously announced underwritten public offering of 14,670,000 shares of its common...
TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
MALVERN, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at...
TELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced that it has commenced an underwritten public offering of shares of its common stock and,...
TELA Bio to Announce Third Quarter 2024 Financial Results
MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2024 financial results on...
TELA Bio, Inc. (TELA) Q2 2024 Earnings Call Transcript
TELA Bio, Inc. (NASDAQ:TELA ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President of Gilmartin Group Antony Koblish - Co-founder, President & CEO Roberto Cuca - COO & CFO Conference...
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.46 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports